Last reviewed · How we verify
Bispecific antibody for PD-L1 and VEGF-A
Bispecific antibody for PD-L1 and VEGF-A is a Biologic drug developed by BioNTech SE. It is currently in Phase 1 development.
At a glance
| Generic name | Bispecific antibody for PD-L1 and VEGF-A |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bispecific antibody for PD-L1 and VEGF-A CI brief — competitive landscape report
- Bispecific antibody for PD-L1 and VEGF-A updates RSS · CI watch RSS
- BioNTech SE portfolio CI
Frequently asked questions about Bispecific antibody for PD-L1 and VEGF-A
What is Bispecific antibody for PD-L1 and VEGF-A?
Bispecific antibody for PD-L1 and VEGF-A is a Biologic drug developed by BioNTech SE.
Who makes Bispecific antibody for PD-L1 and VEGF-A?
Bispecific antibody for PD-L1 and VEGF-A is developed by BioNTech SE (see full BioNTech SE pipeline at /company/biontech-se).
What development phase is Bispecific antibody for PD-L1 and VEGF-A in?
Bispecific antibody for PD-L1 and VEGF-A is in Phase 1.